References

  1. Benjamin EJ, Virani SS, Callaway CW, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 at-a-glance. https://healthmetrics.heart.org/wp-content/uploads/2019/02/At-A-Glance-Heart-Disease-and-Stroke-Statistics-%E2%80%93-2019.pdf. Accessed January 10, 2020.
  2. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf. Accessed January 10, 2020.
  3. American Heart Association. HDL (good), LDL (bad) cholesterol and triglycerides. https://www.heart.org/en/health-topics/cholesterol/hdl-good-ldl-bad-cholesterol-and-triglycerides. Accessed January 10, 2020.
  4. Centers for Disease Control and Prevention. Women and heart disease. https://www.cdc.gov/heartdisease/women.htm. Accessed January 10, 2020.
  5. Centers for Disease Control and Prevention. Heart disease fact sheet. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_disease.htm. Accessed January 10, 2020.
  6. National Institutes of Health. Ischemic heart disease. https://www.nhlbi.nih.gov/ health-topics/ischemic-heart-disease. Accessed January 10, 2020.
  7. Salami JA. Warriach H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2(1):56-65.
  8. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. [Epub ahead of print April 23, 2019]. BMJ Open. doi: 10.1136/bmjopen-2018-023085.
  9. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
  10. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-366.
  11. What you need to know about dietary supplements. US Food and Drug Administration website. https://www.fda.gov/food/dietarysupplements/usingdietarysupplements/ucm109760.htm. Updated November 2017. Accessed January 10, 2020.
  12. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. April 18, 2016;81(74):22612-22613.
  13. Kolber MR, Nickonchuk T, Turgeon R. Do PCSK9 inhibitors reduce cardiovascular events? Can Fam Physician. 2018;64(9):669.
  14. Rosenson N, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72(3):314-329.
  15. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. [Epub ahead of print January 31, 2013]. Chocrane Database Syst Rev. doi: 10.1002/14651858.CD004816.pub5
  16. Pharmacy Times. FDA approves first PCSK9 inhibitor. https://www.pharmacytimes.com/news/fda-approves-first-pcsk9-inhibitor. Published July 24, 2015. Accessed January 10, 2020.
  17. MedPage Today. Second PCSK9 inhibitor approved for CV prevention. https://www.medpagetoday.com/cardiology/prevention/79498. Accessed January 10, 2020.
  18. McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory from the American Heart Association. Circulation. 2019;139(9):e44-e54.
  19. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018;(328):1-8.
  20. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261-1271.
  21. Our World in Data. Does the news reflect what we die from? https://ourworldindata.org/does-the-news-reflect-what-we-die-from. Published May 29, 2019. Accessed January 10, 2020.
  22. American Heart Association. Understand your risks to prevent a heart attack. https://www.heart.org/en/health-topics/heart-attack/understand-your-risks-to-prevent-a-heart-attack. Accessed January 10, 2020.
  23. National Institutes of Health. Atherosclerosis. https://www.nhlbi.nih.gov/health-topics/atherosclerosis. Accessed January 10, 2020.
  24. Furie MB, Mitchell RN. Plaque attack: one hundred years of atherosclerosis in The American Journal of Pathology. Am J Pathol. 2012;180(6):2184-2187.
  25. Insull W JR. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.
  26. National Institutes of Health. Heart attack. https://www.nhlbi.nih.gov/health-topics/heart-attack. Accessed January 10, 2020.
  27. National Institutes of Health. Stroke. https://www.nhlbi.nih.gov/health-topics/stroke. Accessed January 10, 2020.
  28. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical Care in diabetes—2019. Diabetes Care. 2019;42(suppl 1):S103-S123.
  29. National Institutes of Health. Omega-3 fatty acids. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/. Updated October 17, 2019. Accessed January 10, 2020.
  30. Goel A, Pothineni NV, Singhal M, Paydak H, Saldeen T, Mehta JL. Fish, Fish Oils and Cardioprotection: Promise or Fish Tale? Int J Mol Sci. 2018;19(12):1-13.
  31. Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018;3(3):225-234.
  32. Sherratt SCR, Mason Rp. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335-338.
  33. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25(1):46-52.
  34. Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467-474.
  35. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. [Epub ahead of print November 3, 2011]. J Clin Lipidol. doi: 10.1016/j.jacl.2011.10.018.